Icon
+91 94997 68112
Login Register

Zyvox - (600 mg Tablet; Oral)

Linezolid Pfizer
600 mg Tablet; Oral
Less Than $1000 mn
Less Than 5
More Than 5
Less Than 5
 None
More Than 5
More Than 5
Used to treat infections cause by gram positive pathogens
Yes
***** **** ** *** ***** *** ** ******* *** **** ***** ** *** ****; *******, ***** *** ** **********. ** ******* **** ** *** *** *** *** *** *********, ******* ** ***** **** *** ** ****** '***-*** **, ****. ***** ****** ***** **** ** **** *** **** ****** *** *** ************ *********. ******* *** ********** **** ****** *** ********* ***** *** ***** ** ********* *** *** *****. ******* ********, ******, ******, ***** **** **** ********* ********. ** ****** ***** ********* **** ****** * ****** ***** **** *.*. ** *** **, ****. ***** ********* ***** *** **** **** ********* ** **** ***** **** *** **** ****** '***. ****** **** ******* ******** ******* *********** ** *** ****** **** ** ****. **** *** ******* ** ****'* *** **** ***********, ****** ***** * **** ******* *********, ******** **** ********* ****** *** ******* '*** (**** **, ****) *** '*** (**** **, ****) ** *** ****** **** ***** *** ***** **** ** ****** *** ***** *********** *** *** ****** *** *** *** **** *********** ** ****** *** **** ****** '*** *** *** **** ****** ********** *** **** *** ***** ***'* *********** ****** ** *********. ****** ******* **** *** ****** ** ******* ******* ** * ****** ******* ** ***'* ***********. **** ****** ***** **** ***** ***** * **** ******* ********, ******, ****** ******** **** ***** *********'* **** ********* ******* '***, '***, '***, '*** (*** ** ******* ****** ** ****)) ***** ** ****** *** *****. ******* *** *** **** ** ****** ******** ******** *** ******** *** ******* ** *** **, ****. ***** **** ******** ******* ** *** **, ****.
Zyvox Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8
**** *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** *********
******** *** ********* *** ********* ******* ********* ** ****** ** ***** *** ********* *** ********* *** ********* *** *********
****** *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
**** *** \ *** -**- *** ********* ************ ******** ** *** **, ****
******** ** \ ** -**- ******* ******** ******* ********* **** ******
****** ** \ ** -**- *** ********* ******** ******** ** *** **, ****
  1. *** **, **** : ****** ******** ****** ***** *** **** *** ******* ***** **** **** ** ** *** ****** '*** - *** **, ****.
  2. *** **, **** : ****** **** ****** ** ******** ******** ** ********.
  3. *** **, **** : ********** **** ****** *** ********* ***** *** ***** ** ********* *** *** *****.
  4. *** **, **** : ****** **** ***** ***** * **** ******* *********, ******** **** ********* ****** *** ******* ** ** ***** *** ***** **** ** ****** *** ***** *********** *** *** ****** *** *** *** **** *********** ** ****** *** **** ****** '*** *** *** **** ****** ********** *** **** *** ***** *** *********** ****** ** *********. ****** ******* **** *** ****** ** ******* ******* ** * ****** ******* ** ***'* ***********.
  5. *** **, **** : ****** **** ***** ***** ********** **** ****** *** ******** **** ******* '***, '***, '***, '*** (*** ** ******* ****** ** ****))
  6. *** **, **** : ******, ******, ********, ******, *******, ******, ***** ******** ******** *** ******** *** *******.
  7. *** *, **** : ****** **** ***** **** ****** *** **** **** ************ ** ******* '*** *** '*** (***-** ******* ****** ** ****)
  8. *** **, **** : ****** *** ***** ********* ********** ********** ****** '*** **** ********.
  9. *** *, **** : ****** *** ***** ******* ********** **** ********. ***********, ******** ** ******** **** ************* ** ******* *** ******* ****** ********** ** '*** ******
  10. *** **, **** : ****** *** ***** ****** ********** **** ****** *** ****. ********* ** ********** *********, ****** ** ******** **** ************* ** ******* *** ******* ******* ***** ********** ** ******* '*** *** '***.

Zyvox - (2 mg/ ml ; Injection)

Linezolid Pharmacia and Upjohn
2 mg/ ml ; Injection
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
 None
More Than 5
More Than 5
Used in Treatment of infection cause due to gram positive pathogens.
Yes
**** *** *** ***** ** **** **** ** **** ******* *******-*** **, **** & *******- *** **, ****. ****** ***** * **** ******* **** ********* **** *** ***** ****** ***. '***. ** ****** **** **** ****'* ******** ******* ** **** ****. **** *** ****** ** ** ****** **** *** ****** ******* * ********** ********* ** *** ***** ** ***** **** ******** *** ******* ** *** ****. * ****** ***** ****'* ****** ******* *** ****** ******** *** *******.
Zyvox Patent 1 Patent 2 Patent 3
**** ******* ******* *** *********
****** *** ********* ******* *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
**** *** \ ** *** **** ******* ******** ******** ** *** **, ****
****** ** \ ** *** **** ******* **** ****** **** ********
  1. *** **** : **** ******** ****** ***** *** **** ** ****** **** ***** *** ****** '***, *** '***.
  2. *** **** : ****** ***** * **** ******* **** ** ******** ***** ** ******** **** *** ***** ****** ('***) **** ** ******** ** ****.
  3. *** **, **** : **** *** ****** ******* **** * **********, ***** *** ***** *** *** *****.
  4. *** **, **** : ****** ******** ********* & ****** ***** *** **** ** ****** **** ***** *** ****** '***
  5. *** **, **** : ********* & ****** **** ****** **** ************ ** ****** '***
  6. *** **, **** : ********* & ****** ******* ********** **** ****** ** ******* *****.
  7. *** **, **** : **** ******** *** *******.
  8. *** **, **** : ******* *** ****** ******** *** *******

Zyvox - (100 mg/ 5ml; Suspension, Oral)

Linezolid Pharmacia and Upjohn
100 mg/ 5ml; Suspension, Oral
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
 None
Less Than 5
Less Than 5
None
No
Zyvox Patent 1 Patent 2 Patent 3 Patent 4 Patent 5
***** ******* ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** *** \ *** *** **, **** ******* ******** ******** ** *** *, ****
  1. . : ***** ***** * **** ** ** ****** ******* (**** **, ****), *** *** ********* *** ****** ******* (**** **, ****)
  2. *** *, **** : ****** *** ******** *** ******* *****, **** **********. [ *****://***.**********.***.***/**********_****/*********/****/******************.***]
  3. *** **, **** : ********* *** ****** (***** ****) ***** * **** ******* ***** ** ******* ******* , ******* , ******* *** *******
  4. *** *, **** : ********** ********* **** ***** ** ******* ******* , ******* *** *******
  5. *** **, **** : ********** ********* **** ***** ** ****** *******
  6. *** **, **** : ****** ******** ******** **** *** *** ********* *******.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.